Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973697 · ClinicalTrials.gov registry record · Phase 2
Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03973697: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT03973697 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03973697, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of Clostridium difficile infection (C diff).
Interventions
- DRUG Penn Microbiome Therapy - 001
- DRUG Penn Microbiome Therapy - 002
- DRUG Penn Microbiome Therapy - 003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03973697
The ClinicalTrials.gov registry entry for NCT03973697 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Penn Microbiome Therapy - 001 is the first listed.
NCT03973697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03973697 about?
NCT03973697 is a clinical study titled "Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection". This is a randomized, open label, comparative, Phase II study to determine which dose of fecal microbiota transplant using Penn Microbiome Therapy (PMT) products is most effective in treating and preventing recurrence of Clostridium difficile infection (C diff).
What is the current status of trial NCT03973697?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2020-01-13. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03973697?
The interventions under investigation include: Penn Microbiome Therapy - 001 (DRUG), Penn Microbiome Therapy - 002 (DRUG), Penn Microbiome Therapy - 003 (DRUG).
Who is sponsoring clinical trial NCT03973697?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.